Company profile
VivoSight Word leading medical imaging technology
Measure Morphologic and Angiographic Changes Visualize Skin Morphology to a Depth of > 1mm VivoSight DX visualise and quantify treatment effects for: Immune
Updated 06 Jun 2026 16:52
Financial period: 1 Oct 2023 to 30 Sep 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
RP04CS01 | Transaction MzQzNzE3MDU2NGFkaXF6a2N4 | Paper/PDF filed
Published 27 Sep 2024 11:28
MA | Transaction MzQzNTEwMzUyMmFkaXF6a2N4 | Paper/PDF filed
Published 14 Sep 2024 06:58
RESOLUTIONS | Transaction WURCQzQxS1phZGlxemtjeA | Paper/PDF filed
Published 14 Sep 2024 06:46
CS01 | Transaction MzQzMDA5MDIzM2FkaXF6a2N4 | Paper/PDF filed
Published 25 Sep 2024 10:09
Company registered at Companies House
1 Jul 2012 to 30 Jun 2013
Michelson Diagnostics is an independent UK start-up which has launched the world's first CEmarked, FDA-cleared OCT scanner for diagnosis & monitoring of non-melanoma skin cancer and other skin conditions. Our 'VivoSight' scanner is already being used in a small number of dermatology clinics in USA and Germany on a commercial basis and has the support of l...
1 Dec 2007 to 30 Nov 2009
Awaiting Public Summary
